FDA Advisory Committee to Weigh Compounding of BPC-157 and Other Research Peptides

The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to hold a two-day public meeting on July 23-24, 2026 at the agency's White Oak campus to consider whether a group of peptides should be added to the Section 503A bulk drug substances list, which governs the ingredients that traditional compounding pharmacies are permitted to use. According to a notice published in the Federal Register on April 16, 2026, the meeting operates under public docket FDA-2025-N-6895, and written comments received on or before July 9, 2026 were to be provided to the committee for consideration.

The review marks a reversal of course. In September 2023, the FDA placed a set of peptides into an interim category that effectively barred their use in 503A compounding while the agency gathered more information. Regulators cited concerns that included difficulty characterizing the active pharmaceutical ingredient and peptide-related impurities, the potential for aggregation, immunogenicity risk, and, for some substances such as KPV, an absence of human exposure data. Under the FDA's evaluation framework, a nominated substance placed in the more permissive category may be used in compounding while under review, whereas the restrictive category keeps it off the list.

The reconsideration has been driven from the top of the U.S. Department of Health and Human Services. HHS Secretary Robert F. Kennedy Jr. has spoken publicly in favor of peptide therapies as part of his broader health agenda, and trade publications reported that the FDA plans to bring roughly a dozen previously restricted peptides back before advisory panels, with about seven under review at the July meeting and another five expected by February 2027. Reporting on the meeting identified BPC-157, TB-500, KPV and MOTS-c among the substances slated for discussion.

None of the peptides under review is an FDA-approved drug. A favorable recommendation from the committee would not constitute a marketing authorization; it would bear only on whether a substance could be compounded by 503A pharmacies from bulk material. The distinction is significant, because compounded preparations are not FDA-approved and are not reviewed by the agency for safety, effectiveness or manufacturing quality before they reach patients.

The PCAC's role is strictly advisory. The committee votes and issues recommendations, but the FDA makes the final determination and is not bound to follow the panel's advice. Industry observers, including executives at telehealth companies that have offered compounded products, framed the review as a potential path to move certain peptides out of a legal gray zone, while patient-safety advocates have noted that the original 2023 concerns about impurities and limited clinical data have not been resolved by the scheduling of a hearing.

The outcome of the July meeting remained uncertain as of this writing, and the agency had not announced a final decision on any of the nominated substances. Readers should treat the meeting as a procedural step in an ongoing regulatory process rather than a change in the approval status of any peptide.